NCT00940524: Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia |
|
|
| Completed | 1 | 7 | US | Dasatinib, Mitoxantrone, Cytarabine, CONSOLIDATION B-Dasatinib† (dose levels 1-3) *continuously, Cyclophosphamide 4 g/m2 IV (age > or = 60 yrs 3 g/m2), Myeloid growth factor on day 7 until ANC > 1,000/μl x 2 days, CONSOLIDATION C-Dasatinib† (dose levels 1-3) *continuously, Cytarabine 200 mg/m2/d IVCI (continuous infusion), Etoposide 200 mg/m2/d IV, IT Methotrexate 12 mg x 2 (between days 1-7), CONSOLIDATION D-Dasatinib† (dose levels 1-3) *continuously, Pegaspargase 2,000 IU/m2 IV (preferred) or IM day 1 (Patients age > or = 60 yrs receive 1,000 IU/m2), *If Pegaspargase is unavailable, L-asparaginase should be substituted, L-asparaginase 10,000 IU/m2/d IV (preferred) or IM, three times weekly x 6 doses, (Patients age > or = 60 yrs receive 6,000 IU/m2/d IV or IM, three times weekly x 6 doses), Patients in CR will proceed to Maintenance therapy. | Memorial Sloan Kettering Cancer Center, Bristol-Myers Squibb | Leukemia, Acute Lymphoblastic Leukemia | 04/14 | 04/14 | | |
